//= $__courseRemotePath ?>
This course was last updated on
April 30, 2019
CME credit has expired.
//= $videoEmbedCode ?>
In this activity, Bruno Medeiros, MD, and Farhad Ravandi-Kashini, MD, discuss recent advances in the treatment of acute myeloid leukemia (AML). They discuss how new approvals have changed the paradigm for how AML is treated. A central topic in this program is how a better understanding of the molecular genetics of AML has led to new treatments. Dr. Medeiros and Dr. Ravandi-Kashini discuss the pathology and genetics that support the use of new targeted therapies, and the implications of findings from recent clinical trials.
- Acute myeloid leukemia
- Targeted treatment
- FLT3 Tyrosine Kinase Inhibitors
- Isocitrate Dehydrogenase Mutations
- CD33 monoclonal antibodies
- Bispecific antibodies
Bruno Medeiros, MD
Adjunct Clinical Associate Professor of Medicine
Department of Medicine, Hematology
Stanford Comprehensive Cancer Network
Farhad Ravandi-Kashani, MD
MD Anderson Center/University of Texas
Department of Leukemia
Division of Cancer Medicine
Enter your information to begin.
This activity was developed for a national audience of hematologist-oncologists, oncology nurse practitioners, nurses, physician assistants, and other healthcare providers who treat patients with AML.
1.00 AMA PRA Category 1 Credit™.
1.00 ANCC Contact Hour
||April 30, 2019
||April 29, 2020
Other Healthcare Providers
This activity is supported by an independent educational grant from Pfizer, Inc.